Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).

Jatoi, Aminah

Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). [electronic resource] - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer May 2008 - 516-20 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

1556-1380

10.1097/JTO.0b013e31816de276 doi


Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Boronic Acids--administration & dosage
Bortezomib
Carboplatin--administration & dosage
Cardia--pathology
Disease Progression
Esophageal Neoplasms--drug therapy
Esophagogastric Junction--pathology
Female
Humans
Male
Middle Aged
Paclitaxel--administration & dosage
Pyrazines--administration & dosage
Stomach Neoplasms--drug therapy
Survival Rate
Treatment Outcome